Cyclophane and acyclic cyclophane: novel channel blockers of N-methyl-D-aspartate receptor.
The effects of cyclophanes (CPCn, CPPy and TGDMAP) and acyclic cyclophane (ATGDMAP) on various glutamate receptors were studied with these receptors expressed in Xenopus oocytes using voltage-clamp recording. CPCn, CPPy, TGDMAP and ATGDMAP were found to inhibit macroscopic currents at heteromeric NMDA receptors (NR1/NR2), but not Ca(2+)-permeable AMPA receptors (GluR1), Ca(2+)-nonpermeable AMPA receptors (GluR1/GluR2) and metabotropic glutamate receptors (mGluR1alpha). The inhibition of NR1/NR2A receptors by these compounds was more potent than those of the other NMDA receptor subtypes. At a resting potential (-70 mV), the IC(50) values of CPCn, CPPy, TGDMAP and ATGDMAP for NR1/NR2A receptors were 0.5+/-0.1, 1.0+/-0.2, 8.0+/-0.8 and 4.9+/-0.5 microM, respectively. The inhibition by these compounds was voltage-dependent, that is, the degree of inhibition was in the order of negative holding potentials, -100 mV>-70 mV>-20 mV. Results of experiments using mutant NR1 and NR2 subunits identified residues that influence block by CPCn. The inhibition by CPCn was not altered significantly in the mutants at the critical asparagines in the M2 loop, NR1 N616, NR2B N615 and NR2B N616, these residues are known to form the narrowest region of the channel and the binding site of Mg(2+). However, mutations at NR1 N650, located in the vestibule of channel pore, and NR1 D669, located in the extracellular region, reduced the inhibition by CPCn, suggesting that these amino acid residues interact with CPCn. These results suggest that CPCn interacts directly with the mouth or vestibule of the ion channel, like a lid.
Masuko
Takashi
T
College of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi-shi, Chiba 274-8555, Japan.
Nagaoka
Hiroki
H
Miyake
Muneharu
M
Metori
Koichi
K
Kizawa
Yasuo
Y
Kashiwagi
Keiko
K
Igarashi
Kazuei
K
Kusama
Tadashi
T
D000818:Animals; D001392:Azocines / Q000494:pharmacology*; D016923:Cell Death / Q000187:drug effects; D003001:Cloning, Molecular; D047248:Crown Compounds / Q000494:pharmacology*; D004594:Electrophysiology; D004988:Ethers, Cyclic / Q000494:pharmacology*; D009474:Neurons / Q000187:drug effects; D009865:Oocytes / Q000187:drug effects / Q000378:metabolism; D018408:Patch-Clamp Techniques; D010880:Piperidines / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology*; D018091:Receptors, AMPA / Q000187:drug effects; D018094:Receptors, Metabotropic Glutamate / Q000187:drug effects; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*; D014982:Xenopus laevis; D000097566:Cyclophanes
D001392:Azocines; D047248:Crown Compounds; D004988:Ethers, Cyclic; D010880:Piperidines; D011725:Pyridines; D018091:Receptors, AMPA; D018094:Receptors, Metabotropic Glutamate; D016194:Receptors, N-Methyl-D-Aspartate; C518359:N,N'-(6H,12H-5,11-methanodibenzo(b,f)(1,5)diazocine-2,8-diyldi-2,1-ethanediyl)-bis(N-(3-(4-dimethylaminopyridinium)propyl)phenethylamine)dichloride; C121239:cyclophane 1; D000097566:Cyclophanes